B. Riley lowered the firm’s price target on Novavax (NVAX) to $16 from $18 and keeps a Buy rating on the shares following the Q3 report. The firm highlights the company’s increasingly diversified revenue streams.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax call volume above normal and directionally bullish
- Novavax price target lowered to $16 from $18 at B. Riley
- Novavax’s Strong Financial Outlook and Strategic Partnerships Support Buy Rating
- Novavax Reports Q3 2025 Earnings and Strategic Progress
- Novavax’s Q3 2025 Earnings Call: Optimistic Outlook